Clinical Trial Detail

NCT ID NCT04280328
Title Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corvus Pharmaceuticals, Inc.
Indications

multiple myeloma

Therapies

CPI-444 + Daratumumab

CPI-444

Age Groups: adult senior

No variant requirements are available.